Apolipoprotein C-III: From Pathophysiology to Pharmacology

Apolipoprotein C-III (apoC-III) has a critical role in the metabolism of triglyceride (TG)-rich lipoproteins (TRLs). Animal models lacking the APOC3 gene exhibit reduced plasma TG levels, whereas the overexpression of APOC3 leads to increased TG levels. In humans, loss-of-function mutations in APOC3 are associated with reduced plasma TG levels and reduced risk for ischemic vascular disease and coronary heart disease. Several hypolipidemic agents have been shown to reduce apoC-III, including fibrates and statins, and antisense technology aimed at inhibiting APOC3 mRNA to decrease the production of apoC-III is currently in Phase III of clinical development. Here, we review the pathophysiological role of apoC-III in TG metabolism and the evidence supporting this apolipoprotein as an emerging target for hypertriglyceridemia (HTG) and associated cardiovascular disorders.

TrendsApoC-III has a key role in the metabolism of TG-rich lipoproteins.APOC3-knockout animals have reduced plasma TG levels, whereas the overexpression of the APOC3 gene increases TG levels.Loss-of-function mutations in the APOC3 gene decrease plasma TG levels and cardiovascular risk.Current Phase III trials are evaluating an antisense oligonucleotide to APOC3 mRNA.